The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

Sanofi Receives EU Approval for Rezurock to Treat Chronic GVHD

Key Facts

1The European Commission granted conditional marketing authorization for Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD).

2The drug is indicated for adults and children aged 12 years and older with a body weight of at least 40 kg.

3Rezurock provides a new treatment option for patients with limited alternatives after failing previous systemic therapies.

Create Free Account

Version History

2 additional sources confirmed this story

The European Commission has granted conditional marketing authorization for Sanofi's Rezurock (belumosudil), a treatment for chronic graft-versus-host disease (GVHD). This approval applies to adult and pediatric patients aged 12 and older who weigh at least 40 kg. The drug is specifically indicated for those who have previously failed at least two lines of systemic therapy. Rezurock offers a critical new therapeutic option for patients with limited alternatives following stem cell transplants. This regulatory milestone strengthens Sanofi's specialty care portfolio and expands its footprint in the European transplant market. The decision is expected to drive long-term revenue growth within the company's pharmaceutical segment by addressing significant unmet medical needs.